Charles Schwab Investment Management Inc. Buys Shares of 52,657 Chimerix, Inc. (NASDAQ:CMRX)

Charles Schwab Investment Management Inc. purchased a new position in Chimerix, Inc. (NASDAQ:CMRX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 52,657 shares of the biopharmaceutical company's stock, valued at approximately $183,000. Charles Schwab Investment Management Inc. owned about 0.06% of Chimerix as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of CMRX. Assenagon Asset Management S.A. increased its stake in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock worth $2,846,000 after acquiring an additional 496,823 shares during the last quarter. Stoneridge Investment Partners LLC increased its position in shares of Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock valued at $154,000 after purchasing an additional 8,134 shares during the last quarter. Peapod Lane Capital LLC bought a new position in shares of Chimerix during the 4th quarter valued at approximately $2,626,000. Valeo Financial Advisors LLC raised its holdings in Chimerix by 78.8% during the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock valued at $509,000 after buying an additional 64,420 shares during the period. Finally, Palumbo Wealth Management LLC bought a new stake in Chimerix in the fourth quarter worth $221,000. Hedge funds and other institutional investors own 45.42% of the company's stock.

Chimerix Price Performance

CMRX stock remained flat at $8.53 during trading on Friday. 4,547,755 shares of the company traded hands, compared to its average volume of 2,166,256. Chimerix, Inc. has a 52 week low of $0.75 and a 52 week high of $8.54. The firm has a 50-day moving average of $6.32 and a 200 day moving average of $3.39. The stock has a market cap of $800.15 million, a price-to-earnings ratio of -9.07 and a beta of -0.18.

Chimerix (NASDAQ:CMRX - Get Free Report) last issued its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.31 million. As a group, analysts anticipate that Chimerix, Inc. will post -0.99 earnings per share for the current year.

Insider Buying and Selling at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 20,760 shares of company stock valued at $91,175 in the last ninety days. Corporate insiders own 13.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CMRX. HC Wainwright reiterated a "neutral" rating and set a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush reissued a "neutral" rating and issued a $8.55 price objective (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group restated a "hold" rating and set a $8.50 target price (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, StockNews.com assumed coverage on Chimerix in a research note on Monday, March 31st. They set a "hold" rating on the stock.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.